Pfizer Inc. (NYSE:PFE - Get Free Report) Director Scott Gottlieb purchased 1,000 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Pfizer Trading Down 0.8 %
Shares of NYSE:PFE opened at $28.29 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The company's 50-day moving average price is $29.05 and its 200 day moving average price is $28.56. The company has a market cap of $160.31 billion, a PE ratio of 38.23, a P/E/G ratio of 0.90 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54.
The real reason Elon is fully endorsing Trump
From Porter & Company | Ad
Elon Musk is one of mankind’s greatest innovators.
But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk.
This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
Watch this new documentary and you’ll discover what Elon knows,
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the previous year, the firm posted ($0.17) earnings per share. The business's revenue was up 31.2% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.94%. The ex-dividend date is Friday, November 8th. Pfizer's dividend payout ratio is currently 227.03%.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA increased its position in shares of Pfizer by 3.2% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 71,794,056 shares of the biopharmaceutical company's stock valued at $2,008,798,000 after purchasing an additional 2,241,609 shares during the period. Van ECK Associates Corp grew its holdings in Pfizer by 2.8% during the third quarter. Van ECK Associates Corp now owns 16,560,256 shares of the biopharmaceutical company's stock worth $477,929,000 after acquiring an additional 456,168 shares during the period. Federated Hermes Inc. boosted its stake in shares of Pfizer by 3.3% during the 2nd quarter. Federated Hermes Inc. now owns 14,923,545 shares of the biopharmaceutical company's stock worth $417,561,000 after acquiring an additional 470,003 shares in the last quarter. National Pension Service boosted its stake in Pfizer by 18.1% in the 3rd quarter. National Pension Service now owns 11,516,769 shares of the biopharmaceutical company's stock worth $333,295,000 after purchasing an additional 1,762,520 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in Pfizer by 2.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company's stock worth $287,077,000 after purchasing an additional 238,850 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several brokerages have recently weighed in on PFE. Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. StockNews.com raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Wednesday, October 9th. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a "neutral" rating to an "outperform" rating and raised their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 target price on the stock. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and an average price target of $33.58.
Read Our Latest Analysis on PFE
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
